Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Kolesnik, E; Scherr, D; Rohrer, U; Benedikt, M; Manninger, M; Sourij, H; von, Lewinski, D.
SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Int J Mol Sci. 2022; 23(3): Doi: 10.3390/ijms23031678 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Kolesnik Ewald

Scherr Daniel

Co-authors Med Uni Graz

Benedikt Martin

Manninger-Wünscher Martin

Rohrer Ursula

Sourij Harald

von Lewinski Dirk

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are gaining ground as standard therapy for heart failure with a class-I recommendation in the recently updated heart failure guidelines from the European Society of Cardiology. Different gliflozins have shown impressive beneficial effects in patients with and without diabetes mellitus type 2, especially in reducing the rates for hospitalization for heart failure, yet little is known on their antiarrhythmic properties. Atrial and ventricular arrhythmias were reported by clinical outcome trials with SGLT2 inhibitors as adverse events, and SGLT2 inhibitors seemed to reduce the rate of arrhythmias compared to placebo treatment in those trials. Mechanistical links are mainly unrevealed, since hardly any experiments investigated their impact on arrhythmias. Prospective trials are currently ongoing, but no results have been published so far. Arrhythmias are common in the heart failure population, therefore the understanding of possible interactions with SGLT2 inhibitors is crucial. This review summarizes evidence from clinical data as well as the sparse experimental data of SGLT2 inhibitors and their effects on arrhythmias.

Find related publications in this database (Keywords)

SGLT2 inhibitors

atrial fibrillation

arrhythmias

ventricular arrhythmias

© Med Uni Graz • Imprint